Derm-Biome Pharmaceuticals is focused on developing innovative topical therapies aimed at treating inflammatory skin diseases, precancerous skin conditions, and non-melanoma skin cancers. The company has made significant strides in preclinical research, particularly with a topical anticancer treatment that has shown promising results in trials. In a study involving UV-induced skin cancer in mice, the application of Derm-Biome's compound prior to UV exposure led to a notable reduction in the number and size of precancerous lesions, as well as blocking the progression of squamous cell carcinoma tumors. This compound has demonstrated a significant protective effect without any observable toxicity or side effects, indicating its potential as a safer alternative to existing treatments that often come with debilitating side effects.

In addition to its therapeutic developments, Derm-Biome Pharmaceuticals has secured a $450,000 Applied Research and Development grant to support its preclinical research activities. This funding will facilitate collaboration with TransBIOtech, enhancing the company's ability to validate the efficacy of its products and advance its pipeline towards clinical trials. The overarching goal of Derm-Biome is to create effective and well-tolerated topical therapies that address the significant unmet needs in skin health, particularly for conditions like actinic keratosis, which affects millions of individuals annually.

Canada

Derm-Biome Pharmaceuticals, Inc. is a Vancouver-based preclinical biopharmaceutical company founded in 2018 focused on developing and advancing safe and effective topical therapies for inflammatory skin disease, acne, and other skin conditions. The company is also involved in research related to skin cancer and healthy aging.

Derm-Biome Pharmaceuticals

Company Details